{
  "docId": "019dd923-622c-750b-8b9a-4b91788fc785",
  "docSlug": "5fadb686cc03",
  "documentTitle": "Twist Bioscience (TWST)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2022-11-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2941177,
  "pageNumber": 54,
  "pageCount": 236,
  "prevPage": 53,
  "nextPage": 55,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a Q&A format to validate the thesis that the technology is fundamentally flawed.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-4b91788fc785/54",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785#slide-54",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "You basically have to go down the drain with it.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0932-77cf-bfe7-f9d70141118d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "A: “Even at Agilent, we decided that doing next-generation sequencing on these oligonucleotides is very time-consuming and very costly. As a result, we started to develop a much more rapid mass spectroscopy solution to determine the base pair errors in oligonucleotide sequences. I don’t know where they are. They haven’t completed it yet. When we made the decision to back out of the Gen9 deal, we sold our 62% to Ginkgo, and I think we pretty much got out of the oligonucleotide sales business to a synthetic biology company.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95781b04-2ef2-4661-becf-d6b8dc4d5374",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.9,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "Q: “And you guys got out of it because there was no way to make money? Was it too laborious and difficult?”\nA: “Yeah, there was no way to make money. I can’t tell you the details, but every month at [redacted], we reviewed the revenues, and it was just a very costly process, most of which was in quality control. It was also very costly because it required a very long turnaround time. So, contract generation with the customer base was very slow. We ended up most of the time with a bunch of pissed-off customers because we promised them 30 days, and we were out in 60 days, and we still didn’t have the quality control. When you move it down the process, when you get to the point in the process where you need to do a sequence on the gene, and you find out that it has too many errors and has to be wasted, that is an extraordinarily expensive process because you’ve put in so much value in making the DNA, making the oligos, stitching the oligos together to create DNA, genes, and then you’re all the way down the process, and you found out that you have too many errors in the sequence and you have to then basically waste the process. You can’t recycle any of it. You basically have to go down the drain with it.” -Longtime oligonucleotide manufacturing expert and executive; ex-Agilent",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b985773-ba57-4691-b588-3eeba21cc815",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "Agilent exited oligo manufacturing because “there was no way to make money”; “very time-consuming and very costly”; errors and quality control were the fatal flaw; “extraordinarily expensive process” resulting in “pissed-off customers”; “have to go down the drain”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ace89731-9789-4f7a-89f6-58352efb07cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“Even at Agilent, we decided that doing next-generation sequencing on these oligonucleotides is very time-consuming and very costly... We ended up most of the time with a bunch of pissed-off customers... You basically have to go down the drain with it.” — Longtime oligonucleotide manufacturing expert and executive; ex-Agilent",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-0932-77cf-bfe7-fe266115439a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b6c4d34-7358-4b45-953d-f6d1395dce48",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "An ex-Agilent executive involved with their Gen9 investment described the “DNA chip” - the same technology that Twist uses - as a colossal failure plagued by errors, out-of-control costs, and unfixable quality control and yield defects, leading Agilent to exit the oligo manufacturing business entirely: “too many errors”; “very time-consuming and very costly”; “no way to make money”; “extraordinarily expensive process”; long turnaround times leading to a “bunch of pissed off customers.”",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "394adf5c-6efa-4d13-bd34-405d187ce641",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "antagonist-introduction",
      "slug": null,
      "matchId": "7ffa8ae3-634f-4be7-bcd7-a323f25877d1",
      "evidence": "The slide frames the technology as a 'colossal failure' and uses expert testimony to discredit it.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}